GlaxoSmithKline Pharma Q1FY26: Profit Rises 12.7% YoY Despite Flat Revenue; Stock Falls 7.5% on QoQ Weakness

Mumbai, August 1, 2025 – GlaxoSmithKline Pharmaceuticals Ltd (NSE: GLAXO, BSE: 500660) has announced the quarterly results (Q1FY26). The company reported an increase of 12.7% (Year on Year) in net profit at ₹205 crore. However, the quarter-to-quarter figures were all negative except for a 7.5% increase in other income. Q1FY26 is the first quarterly result in the past two years where the company has reported a QoQ revenue decline.

Key Financial Highlights

In Q1FY26, the company reported a marginal 0.2% YoY dip in total income at ₹848.89 crore, with revenue from operations down 1.2%. Despite lower income, PAT rose 12.5% YoY to ₹205.01 crore due to a 5.2% fall in expenses. However, QoQ performance declined, with PAT, PBT, and EPS all down over 22%. Other income grew 22.7% YoY and 7.5% QoQ, cushioning profitability.

Standalone Performance Snapshot

The company reported revenue of ₹804.83 crore in Q1FY26, slightly down from ₹811 crore YoY. Net profit rose 12.7% to ₹204.70 crore, driven by effective cost controls and a 5% YoY drop in expenses. EPS improved to ₹12.08 from ₹10.72. Despite flat top-line growth, margin strength and operational efficiency supported bottom-line expansion.

Segment Overview

The company continues to operate in a single business segment — pharmaceuticals — and thus does not provide a segmental break-up. The performance was supported by better cost optimisation in raw material sourcing and operating efficiencies.

Dividend Update

GSK Pharma confirmed that a final dividend of ₹42 per share for FY25 had been approved at the AGM held on June 27, 2025. This reflects the company’s steady dividend track record, in line with its historical payouts.

Management Commentary

Managing Director Bhushan Akshikar stated, “We remain committed to driving long-term growth through innovation and operational efficiency. Our consistent performance reflects our focus on core therapeutic areas and patient-centric strategies.”

GlaxoSmithKline Share Movement

The share traded at ₹2926 (down by 7.48% from the previous day’s close) at 03:00 PM on Friday. The stock opened at ₹3,162.90 and hit a high of ₹3,184.30 and low of ₹2,912.10 today. The total volume remained pretty decent with a volume of 1.82 lakh shares and ₹53.36 crore traded value. The stock has a high P/E of 57.67 (Industrial Average 36.05) with a strong ROE of 47.54%. After today’s crash, the stock has declined by 12.32% in the past three months.

Strategic Outlook

Despite a muted topline, GlaxoSmithKline Pharma sustained profitability through robust expense management. The company is expected to maintain a stable outlook driven by its prescription drug portfolio and potential launches under regulatory review.

Company Overview

GlaxoSmithKline Pharmaceuticals Ltd, listed on BSE and NSE, is a subsidiary of GSK plc (UK), and one of India’s leading pharmaceutical companies, engaged in manufacturing, distributing, and marketing prescription medicines across therapeutic areas, including respiratory, dermatology, and anti-infectives.

REF:https://nsearchives.nseindia.com/corporate/GLAXO1924_01082025123825_Outcomeofmeeting.pdf

Disclaimer:  At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations